Heron Therap

Q2 FY2026 EarningsQ2 FY26 results missed consensus on the top and bottom lines, with revenue of $37.7M vs. $42.2M expected and a GAAP EPS loss of $0.03 vs. the $0.005 loss expected. While the Acute Care franchise grew 43.9% YoY, the Oncology segment declined 15.9% due to legal uncertainty surrounding CINVANTI. Management has withdrawn FY26 guidance and is exploring strategic alternatives, significantly increasing the risk profile.